tirzepatide and kidney damage SURPASS-4: slows disease in adults with type 2 diabetes, CV risk Tirzepatide reduces kidney damage and

Technical Specifications Compound: BPC-157 (Synthetic Pentadecapeptide) Format: Lyophilized peptide powder Strength: 10 mg per vial Purity: 9899% (COA included) Appearance: White lyophilized powder Category: Research peptide reagent Intended Use This product is intended strictly for: Laboratory experimentation In-vitro scientific research Biochemical and molecular studies Non-human preclinical model development Institutional or academic research programs Not intended for: Human or animal consumption Injection, ingestion, inhalation, or topical use Medical, therapeutic, diagnostic, or cosmetic purposes This compound is not approved by Health Canada, FDA, or any regulatory authority for clinical use

The medication comes from licensed 503A compounding pharmacies and requires no insurance or membership

Smaller, more frequent meals are usually easier than three large ones

Adjustments should be made under medical supervision to balance efficacy and safety

Refrigeration is recommended to keep the suppositories in solid form